Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013.
EASL Clinical Practice Guidelines. Management of hepatitis C virus infection. J Hepatol. 2011;55:245–64.CrossRef
Asselah T, Marcellin P. Interferon free therapy with direct acting antivirals for HCV. Liver Int. 2013;33:93–104.PubMedCrossRef
Hezode C, Dorivol C, Zoulim F, et al. Safety and efficacy of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in 497 cirrhotic non responders. Week 16 analysis of the French early access program (ANRS CO20-CUPIC) in real-life setting. Hepatology. 2012;56(Suppl):217A.
Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2010;376:1467–75.PubMedCrossRef
Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis c genotype 1. NEJM. 2012;266:216–24.CrossRef
•• Gane EJ, Stedman CA, Hyaland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. NEJM. 2013;368:34–44. One of the initial studies with sofosbuvir, which demonstrated possibility of high SVR rates with all oral DAA regimen
Lin C. Hepatitis C viruses: genomes and molecular biology. In: Tan SL, editor. Norkfolk; 2006. Chapter 6.
Clark VC, Peter JA, Nelson DR. New therapeutic strategies in HCV: second generation protease inhibitors. Liver Int. 2013;33:80–4.PubMedCrossRef
Pawlotsky JM. NS5A inhibitors in the treatment of hepatitis C. J Hepatol.
Poenisch M, Bartenschlager R. New insights into structure and replication of the hepatitis C virus and clinical implications. Semin Liver Dis. 2010;30:333–47.PubMedCrossRef
Koch U, Narjes F. Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. Curr Top Med Chem. 2007;7:1302–29.PubMedCrossRef
Aghemo A, De Francesco R. New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology. 2013.
McCown MF, Rajyaguru S, Le Pogam S, et al. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother. 2008;52:1604–12.PubMedCrossRef
Jacobson I, Dore GJ, Foster GR, et al. Simeprevir (TMC 435) Peginterferon/Ribavirin for Chronic HCV Genotype-1 Infection in Treatment-Naïve Patients: Results from QUEST-1, A Phase III Trial. 48th Annual Meeting of the European Association for the Study of the Liver, Abstract 1425; 2013.
Manns M, Marcellin P, Poordad F, et al. Simeprevir (TMC 435) Peginterferon/Ribavirin for Chronic HCV Genotype-1 Infection in Treatment-Naïve Patients: Results from QUEST-2, A Phase III Trial. 48th Annual Meeting of the European Association for the Study of the Liver, Abstract 1413; 2013.
Lawitz E, Forns X, Zeuzem S, et al. Simeprevir (TMC 435) Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype-1 Infection in Patients Who Relapsed After Previous Interferon Based Therapy: Results from PROMISE, A Phase III Trial. Digestive Disease Week, Abstract 869; 2013.
Ferenci P, Asselah T, Foster GR, et al. Faldaprevir plus Pegylated Interferon alfa-2a and Ribavirin in Chronic HCV Genotype-1 Treatment Naïve Patients: Final Results from STARTVerso1, A Randomised, Double-Blind, Placebo-Controlled Phase III Trial. 48th Annual Meeting of the European Association for the Study of the Liver, Abstract 1416, 2013.
•• Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. NEJM. 2013;368:1878–87. One of only few phase 3 studies for all oral therapy. Results demonstrated noninferiority of sofosbuvir and ribavirin compared to current standard of care for genotype 2 and 3 patients
•• Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. NEJM. 2013;368:1867–77. One of only few phase 3 studies for all oral therapy. Results stressed the difference between genotype 2 and genotype 3 HCV treatment
Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology. 2012;55:742–8.PubMedCrossRef
Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol. 2013;58:655–62.PubMedCrossRef
Lalezari JP, Nelson DR, Hyland RH, et al. Once daily sofosbuvir plus ribavirin for 12 and 24 weeks in treatment-naïve patients with HCV infection: the QUANTUM study. J Hepatol. 2013;58:S346.CrossRef
Osinusi A, et al. High efficacy of sofosbuvir with weight-based ribavirin for 24 weeks in difficult-to-treat patients. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, abstract 157LB; 2013.
•• Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. NEJM. 2013;368:45–53. Important study demonstrating importance of IFN-nonresponsiveness in efficacy with all oral DAA regimens
Zeuzem S, Soriano V, Asselah T, et al. Interferon (IFN)-free combinationtreatment with HCV NS3/4A protease inhibitor BI 201335 and the non-nucleoside NS5B inhibitor BI 207127 +/− ribavirin (R): final results of SOUND-C2 and predictors of response. Hepatology. 2012;56(Suppl):308A–9A.
• Kowdley KV, Lawitz E, Poordad F, et al. A 12-week interferon-free treatment regimen with ABT-450/r, ABT-267, ABT-333 abd ribavirin achieves SVR rates (observed data) of 99% in treatment-naïve patients and 93% in prior null responders with HCV genotype 1 infection. Hepatology. 2012;56(Suppl):306A. Important study showing high SVR rates in previous null responders.
Abbvie. Press Release. New Data from Abbvie’s Phase IIB AVIATOR Trial Demonstrate High Sustained Viral Response Rates Across Multiple Patient Types with HCV Genotype 1. April 23, 2013.
• Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Sustained virologic response with daclatasvir plus sofosbuvir +/− ribavirin (RBV) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir. J Hepatol. 2013;58:S570. Important study showing that previous failure of treatment with a protease inhibitor does not preclude SVR with another DAA regimen
Gane EJ, Stedman CA, Hyland RH, et al. All-oral sofosbuvir-based 12-week regimens for the treatment of chronic HCV infection: The ELECTRON Study. 48th Annual Meeting of the European Association for the Study of the Liver, Abstract 14, 2013.
Gilead Sciences. Press Release. May 2, 2013.
Lawitz E, Ghalib R, Rodriguez-Torres M. SVR4 Results of a Once Daily Regimen of Simeprevir (TMC435) Plus Sofosbuvir (GS-7977) with or without Ribavirin (RBV) in HCV GT 1 Null Responders. Digestive Disease Week. Orlando, May 18–21, 2013. Abstract Sa2073.
Everson GT, Sims KD, Rodriguez-Torres M, et al. Interim analysis of an interferon (IFN)- and ribavirin (RBV)-free regimen of daclatasvir (DCV), asunaprevir (ASV), and BMS-791325 in treatment-naïve, hepatitis C virus genotype 1-infected patients. J Hepatol. 2013;58:S573.CrossRef